Anti-TSLP therapies such as Tezspire suppress TSLP signaling, reduce peripheral eosinophil counts, and significantly diminish Th2 cytokine release, improving airway inflammation and reducing the frequency of acute exacerbations in severe asthma (52, 53), thereby validating TSLP’s central role in Th2-driven pathology. Here, TSLP is linked to asthma.